Emergent Biosolutions (NYSE:EBS) will be announcing its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of $0.64 per share for the quarter.
Shares of Emergent Biosolutions (EBS) opened at $47.20 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46. The firm has a market capitalization of $2,320.00, a price-to-earnings ratio of 29.50, a PEG ratio of 0.95 and a beta of 1.32. Emergent Biosolutions has a 52-week low of $27.94 and a 52-week high of $51.25.
A number of analysts have recently weighed in on EBS shares. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Goldman Sachs Group started coverage on Emergent Biosolutions in a research report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 price objective for the company. Finally, Chardan Capital raised their price objective on Emergent Biosolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $51.00.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/emergent-biosolutions-ebs-scheduled-to-post-earnings-on-wednesday.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.